Status:
COMPLETED
Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers
Lead Sponsor:
Novartis
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Instillation of artificial tears is standard treatment in dry eye syndrome and in patients experiencing dry eye symptoms when wearing contact lenses. Povidone K25 eye drops (povidone) is an isotonic s...
Eligibility Criteria
Inclusion
- Healthy subjects
- Older than 18 years
- Ocular discomfort less than 20 mm on 100 mm visual analogue scale (VAS) prior to treatment
Exclusion
- Known hypersensitivity to any of the constituents of the medications
- Known allergic disposition (e.g. hay fever)
- Wearing of contact lenses
- Any kind of current eye disease (e.g. dry eye)
- Additional exclusion criteria are defined in the protocol
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2004
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00135824
Start Date
March 1 2004
End Date
May 1 2004
Last Update
November 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational Site
Heidelberg, Germany, 69120